



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,491	04/18/2007	Heidi Ackerly	P5104R1	1304
9157	7590	05/01/2009	EXAMINER	
GENENTECH, INC.			NATARAJAN, MEERA	
1 DNA WAY			ART UNIT	PAPER NUMBER
SOUTH SAN FRANCISCO, CA 94080			1643	
			MAIL DATE	DELIVERY MODE
			05/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/553,491	ACKERLY ET AL.
	Examiner	Art Unit
	MEERA NATARAJAN	1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 10/14/2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-84 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-84 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ . | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

1. The numbering of the claims is not consistent. Numbers 3-5 have been assigned twice and claim number 32 is missing. The claims have been renumbered consistently from 1 to 84. Applicant is advised to submit a new claim set with the appropriate claim numbering.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-25, 36, 38, 40, 42 drawn to a monoclonal antibody that specifically binds to an oligomeric form of human STOP-1 and said antibody conjugated to an agent.

Group II, claim(s) 26-29, 37, 38, 41, 42 drawn to a STOP-1 polypeptide and a composition comprising said polypeptide.

Group III, claim(s) 30-32, 43 drawn to a nucleic acid molecule encoding the antibody of Group I, a vector comprising said nucleic acid and a host cell comprising said nucleic acid.

Group IV, claim(s) 33-35, drawn to a composition comprising a STOP-1 antagonist and a pharmaceutically acceptable carrier.

Group V, claim(s) 44-48, drawn to a method of producing a STOP-1 polypeptide or STOP-1 antibody.

Group VI, claim(s) 49-52, drawn to a method for diagnosing or monitoring a tumor of a patient.

Art Unit: 1643

Group VII, claim(s) 53-56, 65 drawn to a method of preventing or inhibiting the growth of a tumor that over expresses STOP-1 comprising administering to a patient an antagonist of STOP-1.

Group VIII, claim(s) 57-59, drawn to a method of inhibiting the growth of a cell that over expresses STOP-1 comprising the step of inhibiting the secretion of STOP-1 from the cell.

Group IX, claim(s) 60, drawn to a method for preventing disulfide binding between STOP-1 molecules.

Group X, claim(s) 61-62, drawn to a method for cleaving STOP-1.

Group XI, claim(s) 63, drawn to a method for determining the presence of a STOP-1 polypeptide in a sample.

Group XII, claim(s) 66, 68 drawn to a method of inducing cell migration in vitro comprising administering to a cancer cell or an endothelial cell a STOP-1 polypeptide.

Group XIII, claim(s) 67, 68, drawn to a method of testing the activity of a candidate antagonist or agonist of STOP-1.

Group XIV, claim(s) 69, drawn to a method of treating a disease or condition associated with excessive inappropriate or uncontrolled angiogenesis in a mammalian subject.

Group XV, claim(s) 70-71, drawn to a composition comprising a pharmaceutically acceptable carrier and an immunoadhesin that comprises a STOP-1 polypeptide and an Fc portion of an antibody.

Group XVI, claim(s) 72-75, drawn to a composition comprising a pharmaceutically acceptable carrier and a molecule that potentiates the binding of a STOP-1 polypeptide to a cell surface.

Group XVII, claim(s) 76-77, drawn to a method of inducing angiogenesis in a patient who would benefit from increased angiogenesis by administering a therapeutically effective amount of a STOP-1 potentiatior.

Group XVIII, claim(s) 78-84, drawn to a method for identifying or evaluating a candidate STOP-1 antagonist/potentiator.

Art Unit: 1643

3. The inventions listed as Groups I-XVIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: WO 02/071928 discloses the STOP-1 protein (M450) as well as the nucleic acid encoding it and teaches M450 overexpression in ovarian cancer. Also disclosed are antibodies specific for the said STOP-1 protein and pharmaceutical compositions comprising the said antibodies, as well as method of diagnosing and monitoring ovarian cancer by determining M450 expression.

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- If Group I is elected, applicant is required to elect a corresponding sequence.
- If Group VII is elected, applicant is required to elect a tumor species from those listed in Claim 56.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

5. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The prior art teaches ovarian cancer cells.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1643

8. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEERA NATARAJAN whose telephone number is

Art Unit: 1643

(571)270-3058. The examiner can normally be reached on Monday-Thursday, 9:30AM-7:00PM, ALT. Friday. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MN
/Larry R. Helms/
Supervisory Patent Examiner, Art Unit 1643